CDC said the New York measles outbreak is driving most new cases. Sixty new measles cases were confirmed last week, 52 of which were in New York. There are outbreaks both in New York City and Rockland County, NY. The total number of cases nationwide has reached 764—the highest in 25 years. (CNBC)
Pfizer received early FDA approval for a drug to treat a rare heart disease. Branded Vyndaqel, it’s the first approved for the rare heart condition transthyretin amyloid cardiomyopathy. Also OK’d was a second dosage form, branded Vyndamax. Pfizer set a price of $225,000 a year for the medicine and touted it as a potential blockbuster product. (Reuters)
Lundbeck has bought CBD-focused company Abide Therapeutics for $400 million. The company is developing a cannabinoid platform for new drugs to treat brain diseases. Lundbeck will keep the company’s San Diego headquarters, designating it as a discovery center. (Endpoints)
Hu-manity.co, which employs blockchain to help people claim property rights to their health data, has acquired data firm Betterpath. The acquisition gives Hu-manity.co access to Betterpath’s platforms that find, retrieve and understand complex medical data. (PharmaPhorum)
MM&M’s Transforming Healthcare conference takes place tomorrow. Tickets are still available for the big day. Hear about the convergence of the worlds of health-tech startups, VC and all of the big healthcare industry stakeholders. (MM&M)
